Lately, I’ve found myself in the peculiar role of covering stocks that have seen meteoric gains—those big, showy 100%-plus jumpers that have been on a tear, like IonQ ( IONQ ) and Applied Optoelectronics (The mission of Grassroots Trading rests on the following principles: providing objective, unbiased, and balanced research, backed by solid data and completely void of emotional influences or preference for companies; focusing on small- to mid-cap companies, offering the Seeking Alpha investor compelling po ...

evolent 1 Confidential – Do Not Distribute Evolent Health, Inc. Third Quarter 2024 Results November 7, 2024 CONTACT: Seth R. Frank Evolent Investor Relations sfrank@evolent.com Certain statements made in this presentation and in other written or oral statements made by us or on our behalf are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 ("PSLRA"). A forward-looking statement is a statement that is not a historical fact and, without limitation, inclu ...

Evolent Health, Inc. (NYSE:EVH) Q3 2024 Earnings Conference Call November 7, 2024 5:00 PM ET Participants Seth Blackley - Chief Executive Officer John Johnson - Chief Financial Officer Seth Frank - Vice President, Investor Relations Conference Call Participants Charles Rhyee - TD Cowen Jailendra Singh - Truist Securities Jeff Garro - Stephens Stephanie Davis - Barclays Ryan Daniels - William Blair Matthew Gillmor - KeyBanc Kyle Aikman - J.P. Morgan Richard Close - Canaccord Genuity Sean Dodge - RBC Capital ...

Evolent Health (EVH) reported $621.4 million in revenue for the quarter ended September 2024, representing a year-over-year increase of 21.6%. EPS of $0.04 for the same period compares to $0.30 a year ago.The reported revenue compares to the Zacks Consensus Estimate of $625.58 million, representing a surprise of -0.67%. The company delivered an EPS surprise of -86.67%, with the consensus EPS estimate being $0.30.While investors closely watch year-over-year changes in headline numbers -- revenue and earnings ...

Evolent Health (EVH) came out with quarterly earnings of $0.04 per share, missing the Zacks Consensus Estimate of $0.30 per share. This compares to earnings of $0.30 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -86.67%. A quarter ago, it was expected that this health care software and consulting services provider would post earnings of $0.21 per share when it actually produced earnings of $0.30, delivering a surprise of 42. ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 _________________________ FORM 10-Q _________________________ Title of each class Trading Symbol(s) Name of each exchange on which registered Class A Common Stock of Evolent Health, Inc., par value $0.01 per shareEVH New York Stock Exchange (Mark One) S QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR ...

Revenue Performance - Revenue for Q3 2024 was $621.4 million, an increase of $110.4 million or 21.6% compared to Q3 2023[1] - Revenue for the three months ended September 30, 2024, was $621,401 thousand, a 21.6% increase from $511,015 thousand in the same period of 2023[25] - For Q4 2024, revenue is expected to be between $642.0 million and $667.0 million, with Adjusted EBITDA projected between $22.0 million and $37.0 million[12] - Full year 2024 revenue guidance is approximately $2.55 billion to $2.575 billion, with Adjusted EBITDA expected to be between $160.0 million and $175.0 million[13] Profitability and Loss - Net loss attributable to common shareholders was $(31.2) million, with a net loss margin of (5.0)%, an improvement from (6.5)% in Q3 2023[4] - The net loss attributable to common shareholders for the three months ended September 30, 2024, was $(31,231) thousand, compared to a net loss of $(33,196) thousand for the same period in 2023, reflecting an improvement[47] - The company reported a basic and diluted loss per common share of $(0.27) for the three months ended September 30, 2024, compared to $(0.30) in the same period of 2023[25] - Net loss before preferred dividends decreased to $38,821 thousand in September 2024 from $79,629 thousand in September 2023, representing a 51% improvement[28] - The company experienced a loss before income taxes of $(23,756) thousand for the three months ended September 30, 2024, an improvement from $(30,874) thousand in the same period of 2023[25] Adjusted EBITDA - Adjusted EBITDA for the quarter was $31.8 million, resulting in an Adjusted EBITDA margin of 5.1%, down from 9.5% in the same quarter last year[4] - The adjusted EBITDA for the three months ended September 30, 2024, was $31,801 thousand, with an adjusted EBITDA margin of 5.1%, down from $48,714 thousand and 9.5% in the prior year[47] - The company continues to expect average annual revenue growth in excess of 15% and average Adjusted EBITDA growth of 20% on a long-term basis[14] - Adjusted EBITDA margin is expected to provide further insight into operational performance compared to revenues over time, as management focuses on long-term operational costs[39] Operating Expenses - Total operating expenses for the three months ended September 30, 2024, were $637,669 thousand, compared to $528,953 thousand in the prior year, reflecting a 20.6% increase[25] - Adjusted cost of revenue for the three months ended September 30, 2024, was $539,591 thousand, up from $386,534 thousand in the same period of 2023, reflecting a 39% increase[44] - Total selling, general, and administrative expenses for the nine months ended September 30, 2024, were $215,349 thousand, down from $276,682 thousand in the same period of 2023[45] Cash and Liquidity - Cash and cash equivalents decreased to $96,583 thousand as of September 30, 2024, down from $192,825 thousand at the end of 2023[26] - Total current liabilities decreased to $523,683 thousand as of September 30, 2024, from $674,242 thousand at the end of 2023, indicating improved liquidity[26] - Cash and cash equivalents and restricted cash decreased to $127,851 thousand as of the end of September 2024 from $224,498 thousand at the end of September 2023, a decline of 43%[29] - Net cash provided by operating activities was $44,996 thousand for the nine months ended September 30, 2024, compared to $53,201 thousand for the same period in 2023[28] - The net cash used in investing activities was $43,002 thousand for the nine months ended September 30, 2024, compared to $409,492 thousand in the same period of 2023, showing a significant reduction[28] Contracts and Growth - Evolent announced six new contract agreements in Q3 2024, the highest number in the company's history, including a significant oncology Performance Suite agreement[6] - Evolent Health anticipates continued expansion and new partner additions, indicating a focus on growth despite current market dynamics[52] Risks and Challenges - The company faces risks related to the integration of acquisitions and maintaining profitability under performance-based contracts, which could impact future financial results[53] - The company faces risks related to the ability to contain health care costs and maintain adequate reserves for policy benefits[54] - There is a dependency on key personnel, impacting the ability to attract and retain talent[54] - The company has obligations to make material payments to pre-IPO investors for future tax benefits[54] - The company’s debt following the NIA acquisition raises concerns about meeting obligations[54] - There are potential volatility risks for the Class A common stock price, especially if a substantial number of shares are sold[54] - The company does not intend to pay cash dividends on its Class A common stock[54] - Risks related to legal proceedings and the safeguarding of confidential data may impact operations[54] - The company relies on third-party vendors for technology platform maintenance, which poses operational risks[54] - The conditional conversion features of the 2025 and 2029 Notes may adversely affect financial condition[54] - The company operates in a rapidly changing and competitive environment, with new risk factors emerging[55]

Revenue of $621.4 million, an increase of $110.4 million or 21.6%, from the three months ended September 30, 2023. Net loss attributable to common shareholders of Evolent Health, Inc. of $(31.2) million and a net loss margin of (5.0)%. Adjusted EBITDA of $31.8 million resulting in an Adjusted EBITDA margin of 5.1%. Revises outlook for Adjusted EBITDA for 2024. Reiterates average annual long-term revenue and average Adjusted EBITDA growth rate targets. Announces record six new contract agreements in the qua ...

The upcoming report from Evolent Health (EVH) is expected to reveal quarterly earnings of $0.30 per share, indicating no change from the year-ago quarter compared to the year-ago period. Analysts forecast revenues of $625.58 million, representing an increase of 22.4% year over year.Over the last 30 days, there has been a downward revision of 2.4% in the consensus EPS estimate for the quarter, leading to its current level. This signifies the covering analysts' collective reconsideration of their initial fore ...

If you are looking for a stock that has a solid history of beating earnings estimates and is in a good position to maintain the trend in its next quarterly report, you should consider Evolent Health (EVH) . This company, which is in the Zacks Internet - Software industry, shows potential for another earnings beat.This health care software and consulting services provider has seen a nice streak of beating earnings estimates, especially when looking at the previous two reports. The average surprise for the la ...